Platycodin D inhibits diabetic retinopathy via suppressing TLR4 / MyD88 / NF‐κB signaling pathway and activating Nrf2/ HO ‐1 signaling pathway
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14419 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2024. Written by Yanmin Song and 2 co-authors. Institution: Department of Ophthalmology, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi Province, P.R. China. Major MEDLINE topics: Diabetic Retinopathy, Diabetes Mellitus, Saponins, Triterpenes. Cited 19 times so far (Crossref); 38 references.
Abstract (original language)
Diabetic retinopathy (DR) is one of the most frequently occurring diabetic complications associated with inflammation and oxidative stress. Platycodin D (PLD) is a bio‐active saponin that has been reported to exhibit anti‐inflammation, anti‐oxidative, and antidiabetic activities. Therefore, we speculated the protective effects of PLD on DR in the present study. Our results demonstrated that PLD attenuated high glucose (HG)‐induced inflammation, as evidenced by decreased production of TNF‐α, IL‐1β, IL‐6. The HG‐induced oxidative stress was prevented by PLD with decreased ROS production and malondialdehyde (MDA) level, as well as increased activities of superoxide dismutase and glutathione (GSH). In addition, treatment of PLD significantly decreased the apoptotic rate in HG‐induced ARPE‐19 cells. The HG‐caused increases in expression of bax and cleaved capsase‐3, as well a decrease in bcl‐2 expression were attenuated by PLD. Furthermore, PLD suppressed the activation of TLR4/MyD88/NF‐κB and enhanced the activation of Nrf2/HO‐1 pathway in HG‐induced ARPE‐19 cells. Additionally, overexpression of TLR4 attenuated the anti‐inflammatory, while knockdown of Nrf2 reversed the anti‐oxidative and anti‐apoptotic activities of PLD in HG‐stimulated ARPE‐19 cells. Furthermore, PLD attenuates retinal damage in DR rats. Finally, we demonstrated that PLD weakened the TLR4/MyD88/NF‐κB p65 pathway and promoted the Nrf2/HO‐1 pathway in vivo. Taken together, these findings indicated that PLD exerted protective effects against DR, which were attributed to the regulation of TLR4/MyD88/NF‐κB and Nrf2/HO‐1 signaling pathways.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Ophthalmology, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi Province, P.R. China.
- Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi Province, P.R. China.
- Department of Ophthalmology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi Province, P.R. China.
- Department of Ophthalmology, Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, Xi'an, Shaanxi Province, P.R. China.
Cite
APA
Song, Y., Lv, P., & Yu, J. (2024). Platycodin D inhibits diabetic retinopathy via suppressing TLR4 / MyD88 / NF‐κB signaling pathway and activating Nrf2/ HO ‐1 signaling pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14419
Vancouver
Song Y, Lv P, Yu J. Platycodin D inhibits diabetic retinopathy via suppressing TLR4 / MyD88 / NF‐κB signaling pathway and activating Nrf2/ HO ‐1 signaling pathway. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14419
BibTeX
@article{Song2024,
author = {Song, Yanmin and Lv, Peilin and Yu, Jingni},
title = {Platycodin D inhibits diabetic retinopathy via suppressing TLR4 / MyD88 / NF‐κB signaling pathway and activating Nrf2/ HO ‐1 signaling pathway},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14419}
}
EUVIMED